Parexel Los Angeles Early Phase Clinical Unit — Glendale, California

Parexel Los Angeles Early Phase Clinical Unit is a clinical research site located in Glendale, California, United States 91206.

Crixeo Health Trust Score: 62/100 (FAIR). This profile has not yet been claimed by the site owner.

Parexel Los Angeles Early Phase Clinical Unit has participated in 3 clinical trials.

Therapeutic areas: Alcohol Use Disorder (AUD), Cognitive Dysfunction, Schizophrenia.

Sponsors: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, Kynexis B.V..

Sponsor Feasibility Report

Trust Score: 62/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Parexel Los Angeles Early Phase Clinical Unit?

Parexel Los Angeles Early Phase Clinical Unit has a Crixeo Trust Score of 62/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Parexel Los Angeles Early Phase Clinical Unit conducted?

Parexel Los Angeles Early Phase Clinical Unit has 3 clinical trials on record. Their work covers Alcohol Use Disorder (AUD), Cognitive Dysfunction, Schizophrenia.

Is Parexel Los Angeles Early Phase Clinical Unit accredited by Crixeo Health?

Parexel Los Angeles Early Phase Clinical Unit has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Parexel Los Angeles Early Phase Clinical Unit?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.